Initial signals of efficacy in cholangiocarcinoma from a phase Ib trial of varlitinib in combination with doublet chemotherapy (cisplatin + 5-fluororacil or capecitabine)
Chih-Yi Hsieh, Ming-Shiang Wu, Mark McHale, Bertil Lindmark, Lilian Chow, Yee Chao; ASLAN Pharmaceuticals, Taipei, Taiwan; National Taiwan University Hospital, Taipei, Taiwan; ASLAN Pharmaceuticals, Singapore, Singapore; Aslan Pharamaceuticals, Singapore, Singapore; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
ASCO Meeting Abstracts, Abstract #e15671, May 2017
Pan-HER inhibitor, varlitinib (ASLAN001) disrupts HER/ERK signaling and causes apoptosis in triple negative breast cancer cells.
Liu CY, Huang TT, Huang CT, Yang HP, Tseng LM, Shiau CW, Chen KF.
AACR Meeting Abstracts, Apr 2017; 2017: 2087
Phase IIA study to evaluate the biological activity of ASLAN001 in HER-1/2 co-expressing or HER-2 amplified advanced gastric cancer
J. Kim, S. Im, K. Lee, J.W. Kim, K. Lee, S. Han, T. Kim, I.S. Choi, D. Oh, N. Lee, C. Song, M. Foster, M. McHale, A. Barge, W.H. Kim, Y. Bang
Poster, ESMO 2014, 29 Sept 2014
Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
For more details,view the rest of the study here.